Donna Senger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8331582/publications.pdf

Version: 2024-02-01

172457 361022 2,498 36 29 35 citations h-index g-index papers 36 36 36 3073 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Reovirus as an Oncolytic Agent Against Experimental Human Malignant Gliomas. Journal of the National Cancer Institute, 2001, 93, 903-912.	6.3	203
2	Proliferation of Human Glioblastoma Stem Cells Occurs Independently of Exogenous Mitogens. Stem Cells, 2009, 27, 1722-1733.	3.2	175
3	Rapid Retrograde Tyrosine Phosphorylation of trkA and Other Proteins in Rat Sympathetic Neurons in Compartmented Cultures. Journal of Cell Biology, 1997, 138, 411-421.	5.2	153
4	The p75 Neurotrophin Receptor Is a Central Regulator of Glioma Invasion. PLoS Biology, 2007, 5, e212.	5.6	150
5	Myxoma Virus Is a Novel Oncolytic Virus with Significant Antitumor Activity against Experimental Human Gliomas. Cancer Research, 2005, 65, 9982-9990.	0.9	149
6	Efficacy of Systemically Administered Oncolytic Vaccinia Virotherapy for Malignant Gliomas Is Enhanced by Combination Therapy with Rapamycin or Cyclophosphamide. Clinical Cancer Research, 2009, 15, 2777-2788.	7.0	142
7	Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma. Clinical Cancer Research, 2016, 22, 3860-3875.	7.0	142
8	Targeting Human Medulloblastoma: Oncolytic Virotherapy with Myxoma Virus Is Enhanced by Rapamycin. Cancer Research, 2007, 67, 8818-8827.	0.9	97
9	Myxoma Virus Virotherapy for Glioma in Immunocompetent Animal Models: Optimizing Administration Routes and Synergy with Rapamycin. Cancer Research, 2010, 70, 598-608.	0.9	90
10	Effects of Intravenously Administered Recombinant Vesicular Stomatitis Virus (VSV ΔM51) on Multifocal and Invasive Gliomas. Journal of the National Cancer Institute, 2006, 98, 1546-1557.	6.3	88
11	Efficacy and Safety/Toxicity Study of Recombinant Vaccinia Virus JX-594 in Two Immunocompetent Animal Models of Glioma. Molecular Therapy, 2010, 18, 1927-1936.	8.2	83
12	Efficacy and Safety Evaluation of Human Reovirus Type 3 in Immunocompetent Animals. Clinical Cancer Research, 2004, 10, 8561-8576.	7.0	78
13	Proteolytic Disassembly Is a Critical Determinant for Reovirus Oncolysis. Molecular Therapy, 2007, 15, 1512-1521.	8.2	76
14	Renal immune surveillance and dipeptidase-1 contribute to contrast-induced acute kidney injury. Journal of Clinical Investigation, 2018, 128, 2894-2913.	8.2	74
15	Gamma-Secretase Represents a Therapeutic Target for the Treatment of Invasive Glioma Mediated by the p75 Neurotrophin Receptor. PLoS Biology, 2008, 6, e289.	5. 6	66
16	Activation of NOTCH Signaling by Tenascin-C Promotes Growth of Human Brain Tumor-Initiating Cells. Cancer Research, 2017, 77, 3231-3243.	0.9	61
17	ADAM-9 is a novel mediator of tenascin-C-stimulated invasiveness of brain tumor–initiating cells. Neuro-Oncology, 2015, 17, 1095-1105.	1.2	59
18	Long-Term Survivors of Glioblastoma. Cancer Journal (Sudbury, Mass), 2003, 9, 214-221.	2.0	51

#	Article	IF	CITATIONS
19	Novel <i>MSH6</i> Mutations in Treatment-Naïve Glioblastoma and Anaplastic Oligodendroglioma Contribute to Temozolomide Resistance Independently of <i>MGMT</i> Promoter Methylation. Clinical Cancer Research, 2014, 20, 4894-4903.	7.0	51
20	Evidence that Protein Kinase C Activities Involved in Regulating Neurite Growth Are Localized to Distal Neurites. Journal of Neurochemistry, 1994, 63, 868-878.	3.9	47
21	Oncolytic Efficacy of Recombinant Vesicular Stomatitis Virus and Myxoma Virus in Experimental Models of Rhabdoid Tumors. Clinical Cancer Research, 2008, 14, 1218-1227.	7.0	47
22	Glioma invasion mediated by the p75 neurotrophin receptor (p75NTR/CD271) requires regulated interaction with PDLIM1. Oncogene, 2016, 35, 1411-1422.	5. 9	47
23	Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancer. Gene Therapy, 2004, 11, 1579-1589.	4.5	45
24	Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin. Neuro-Oncology, 2013, 15, 904-920.	1.2	44
25	Delivery of newly synthesized tubulin to rapidly growing distal axons of sympathetic neurons in compartmented cultures Journal of Cell Biology, 1996, 135, 701-709.	5.2	43
26	Comprehensive genomic profiling of glioblastoma tumors, BTICs, and xenografts reveals stability and adaptation to growth environments. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 19098-19108.	7.1	42
27	Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells. Oncotarget, 2016, 7, 59360-59376.	1.8	34
28	Spatial requirements for TrkA kinase activity in the support of neuronal survival and axon growth in rat sympathetic neurons. Neuropharmacology, 2003, 45, 995-1010.	4.1	33
29	Spatial Regulation of Neuronal Gene Expression in Response to Nerve Growth Factor. Developmental Biology, 1997, 184, 1-9.	2.0	31
30	ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts. PLoS ONE, 2018, 13, e0202860.	2.5	28
31	Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma. Cancer Research, 2019, 79, 2111-2123.	0.9	28
32	Development of a peptide-based delivery platform for targeting malignant brain tumors. Biomaterials, 2020, 252, 120105.	11.4	15
33	Population-based Study of Medulloblastoma: Outcomes in Alberta from 1975 to 1996. Canadian Journal of Neurological Sciences, 2008, 35, 210-215.	0.5	11
34	The Role of Neurotrophin Signaling in Gliomagenesis. Vitamins and Hormones, 2017, 104, 367-404.	1.7	11
35	Eukaryotic initiation factor 5B (eIF5B) regulates temozolomide-mediated apoptosis in brain tumour stem cells (BTSCs). Biochemistry and Cell Biology, 2020, 98, 647-652.	2.0	4
36	TMIC-02CELL AUTONOMOUS AND CELL NON-AUTONOMOUS ROLES OF p75 NEUROTROPHIN RECEPTOR (p75NTR) IN GLIOMA INVASION. Neuro-Oncology, 2015, 17, v214.6-v214.	1.2	0